{"id":"NCT03135834","sponsor":"Pfizer","briefTitle":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","officialTitle":"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A BIVALENT RLP2086-CONTAINING PENTAVALENT VACCINE (MENABCWY) IN HEALTHY SUBJECTS>=10 TO <26 YEARS OF AGE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-24","primaryCompletion":"2022-10-25","completion":"2022-10-25","firstPosted":"2017-05-01","resultsPosted":"2023-08-08","lastUpdate":"2023-08-08"},"enrollment":1610,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"MenABCWY","otherNames":[]},{"type":"BIOLOGICAL","name":"Saline","otherNames":[]},{"type":"BIOLOGICAL","name":"rLP2086","otherNames":[]},{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":[]}],"arms":[{"label":"Group 1 (ACWY Naive subjects, MenABCWY/Saline)","type":"EXPERIMENTAL"},{"label":"Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)","type":"EXPERIMENTAL"},{"label":"Group 3 (ACWY Experienced subjects, MenABCWY/Saline)","type":"EXPERIMENTAL"},{"label":"Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)","type":"EXPERIMENTAL"}],"summary":"This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studying safety and immunogenicity of a meningococcal pentavalent vaccine.","primaryOutcome":{"measure":"Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)","timeFrame":"1 month after Vaccination 2","effectByArm":[{"arm":"Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM)","deltaMin":74.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":75,"countries":["United States","Czechia","Finland","Poland"]},"refs":{"pmids":["39520893","37579773"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B1971057"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":272},"commonTop":["Injection site pain (PAIN AT INJECTION SITE)","Fatigue","Headache","Myalgia (MUSCLE PAIN)","Arthralgia (JOINT PAIN)"]}}